CRMD beat EPS expectations by 13.12%
May 06, 2025, 10:34 PM
0.00%
What does CRMD do
CorMedix is a pharmaceutical company based in New Jersey, focused on developing therapeutic products, notably DefenCath, an antimicrobial solution for preventing catheter-related bloodstream infections in kidney failure patients. The company went public in 2010 and has also sponsored research on taurolidine for rare pediatric tumors.
CorMedix (CRMD) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, CorMedix's actual EPS was $0.30, beating the estimate of $0.27 per share, resulting in a 13.12% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.